Ivabradine in the Acute Management of Cardiogenic Shock

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07714746

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07714746
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07714746. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-20 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ivabradine in the Acute Management of Cardiogenic Shock
Acronym
IVASHOCK
Condition
Cardiogenic Shock Post Myocardial Infarction
Intervention (Drug)
Ivabradine 5mg Tab
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)

Record details

Record id
cardio:ct-nct07714746
Content hash
4a3aa95bfa5cf0f982f8852b4fe3f54acf157092ef13a34a0d53a3a2302755ce